Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670 is registered in ClinicalTrials.gov with Mediar Therapeutics as lead sponsor.

NCT NCT07287670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Lead sponsor
Mediar Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
April 16, 2026
Completion date
December 31, 2028
Enrollment
85 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis